Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. Among authors: patalano f. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
Addressing unmet needs in the treatment of COPD.
Patalano F, Banerji D, D'Andrea P, Fogel R, Altman P, Colthorpe P. Patalano F, et al. Eur Respir Rev. 2014 Sep;23(133):333-44. doi: 10.1183/09059180.00004014. Eur Respir Rev. 2014. PMID: 25176969 Free PMC article. Review.
FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D. Mahler DA, et al. Among authors: patalano f. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1068-79. doi: 10.1164/rccm.201505-1048OC. Am J Respir Crit Care Med. 2015. PMID: 26177074 Clinical Trial.
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P. LaForce C, et al. Among authors: patalano f. Int J Chron Obstruct Pulmon Dis. 2016 Jun 8;11:1233-43. doi: 10.2147/COPD.S100445. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27354782 Free PMC article. Clinical Trial.
Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Patalano F, Banerji D. Zhong N, et al. Among authors: patalano f. COPD. 2016 Dec;13(6):686-692. doi: 10.1080/15412555.2016.1182970. Epub 2016 Aug 11. COPD. 2016. PMID: 27715335 Clinical Trial.
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D. Vogelmeier C, et al. Among authors: patalano f. Int J Chron Obstruct Pulmon Dis. 2016 Dec 14;11:3189-3197. doi: 10.2147/COPD.S116786. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 28008244 Free PMC article.
87 results